Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron

Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). We are currently evaluating vibegron in a pivotal Phase 3 international clinical trial for the treatment of OAB. We also plan to commence a Phase 3 clinical trial for OAB in men with BPH and a Phase 2a clinical trial for IBS-associated pain by the end of 2018.

LEARN MORE

women-sleeping

Latest News

The latest posts and articles

Urovant Sciences Reports Financial Results…

BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Nov. 12, 2018– Urovant Sciences Ltd. (Nasdaq: UROV),a clinical-stage biopharmaceutical company focused on developing…

Urovant Sciences Completes Patient Enrollment…

More than 1,500 patients enrolled in international Phase 3 clinical trial EMPOWUR, exceeding recruitment target…

Urovant Sciences to Report 2018…

BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Nov. 5, 2018– Urovant Sciences Ltd. (Nasdaq: UROV),a clinical-stage biopharmaceutical company focused on developing…

Copyright 2018 © All Rights Reserved